Aurobindo Pharma Limited
NSE:AUROPHARMA.NS
1528.1 (INR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 290,018.7 | 246,171.3 | 233,665.5 | 245,579.4 | 227,379.6 | 192,259.3 | 161,992.1 | 146,639.4 | 136,493.9 | 120,429.6 | 80,385.9 | 57,827.1 | 45,537.4 | 43,814.8 | 35,754.4 | 30,772.8 | 24,359 | 21,229.2 | 15,936.1 | 13,216 | 15,046 |
| Cost of Revenue
| 180,475 | 112,932.6 | 101,402.8 | 99,024.7 | 97,352.3 | 87,126.4 | 67,527.4 | 64,342.6 | 61,575.4 | 55,056 | 36,060.4 | 29,907.7 | 25,197.6 | 22,418.4 | 15,943.5 | 16,367.4 | 14,226.4 | 12,599.7 | 12,460.2 | 7,694.3 | 9,017.9 |
| Gross Profit
| 109,543.7 | 133,238.7 | 132,262.7 | 146,554.7 | 130,027.3 | 105,132.9 | 94,464.7 | 82,296.8 | 74,918.5 | 65,373.6 | 44,325.5 | 27,919.4 | 20,339.8 | 21,396.4 | 19,810.9 | 14,405.4 | 10,132.6 | 8,629.5 | 3,475.9 | 5,521.7 | 6,028.1 |
| Gross Profit Ratio
| 0.378 | 0.541 | 0.566 | 0.597 | 0.572 | 0.547 | 0.583 | 0.561 | 0.549 | 0.543 | 0.551 | 0.483 | 0.447 | 0.488 | 0.554 | 0.468 | 0.416 | 0.406 | 0.218 | 0.418 | 0.401 |
| Reseach & Development Expenses
| 15,455.4 | 395.1 | 652.4 | 688.1 | 1,217.9 | 756.3 | 292.2 | 165.8 | 150.6 | 253 | 50.9 | 57.6 | 49.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 8,176.9 | 6,624.1 | 6,448.8 | 8,271 | 6,515.9 | 4,247.9 | 4,096.8 | 3,314.4 | 2,647.4 | 2,645.5 | 989.4 | 745 | 648.6 | 3,418.6 | 3,096.1 | 1,489.1 | 1,255 | 698.6 | 616.2 | 536.3 | 580.6 |
| Selling & Marketing Expenses
| 16,847.2 | 16,857.6 | 15,685.8 | 16,432.7 | 15,954.6 | 11,921.6 | 10,901.3 | 11,303.9 | 9,465.2 | 9,342.5 | 3,992.1 | 3,364.3 | 2,309.5 | 0 | 0 | 1,473 | 911 | 744.6 | 543.2 | 566.5 | 523.4 |
| SG&A
| 66,330.3 | 23,481.7 | 22,134.6 | 24,703.7 | 22,470.5 | 16,169.5 | 14,998.1 | 14,618.3 | 12,112.6 | 11,988 | 4,981.5 | 4,109.3 | 2,958.1 | 3,418.6 | 3,096.1 | 2,962.1 | 2,166 | 1,443.2 | 1,159.4 | 1,102.8 | 1,104 |
| Other Expenses
| 5,186 | 2,905.9 | 1,345.6 | 2,257.8 | 652.9 | 1,018.8 | 803.7 | 306.1 | 299.5 | 431.5 | 189.9 | 194.4 | 190 | 9,368 | 8,514.3 | 9,701.8 | 4,613.2 | 4,672.5 | 935.9 | 3,736.6 | 2,947.7 |
| Operating Expenses
| 66,330.3 | 108,102.3 | 99,282.3 | 101,790.6 | 90,611.5 | 72,048.4 | 61,790.5 | 51,875.6 | 46,276.5 | 42,111.8 | 25,564.3 | 20,979.1 | 16,026.5 | 12,786.6 | 11,610.4 | 12,663.9 | 6,779.2 | 6,115.7 | 2,095.3 | 4,839.4 | 4,051.7 |
| Operating Income
| 43,213.4 | 25,514.7 | 33,064.3 | 44,535.7 | 39,400.9 | 33,084.5 | 32,674.2 | 30,421.2 | 28,642 | 23,261.8 | 18,761.2 | 6,940.3 | 4,313.3 | 8,609.8 | 8,200.5 | 1,741.5 | 3,353.4 | 2,513.8 | 1,380.6 | 682.3 | 1,976.4 |
| Operating Income Ratio
| 0.149 | 0.104 | 0.142 | 0.181 | 0.173 | 0.172 | 0.202 | 0.207 | 0.21 | 0.193 | 0.233 | 0.12 | 0.095 | 0.197 | 0.229 | 0.057 | 0.138 | 0.118 | 0.087 | 0.052 | 0.131 |
| Total Other Income Expenses Net
| 758.1 | 610.3 | 663.1 | 28,900.2 | -1,970.5 | -2,171 | -262.4 | 187.2 | -1,417.4 | -1,583.3 | -3,436 | -3,199.2 | -6,442.8 | -624.6 | -678 | -1,015.3 | -436 | -449.6 | -395 | -499.4 | -451 |
| Income Before Tax
| 43,971.5 | 26,125 | 33,727.4 | 73,435.9 | 37,430.4 | 30,913.5 | 32,411.8 | 30,608.4 | 27,224.6 | 21,678.5 | 15,325.2 | 3,741.1 | -2,129.5 | 7,985.2 | 7,522.5 | 726.2 | 2,917.4 | 2,064.2 | 985.6 | 182.9 | 1,525.4 |
| Income Before Tax Ratio
| 0.152 | 0.106 | 0.144 | 0.299 | 0.165 | 0.161 | 0.2 | 0.209 | 0.199 | 0.18 | 0.191 | 0.065 | -0.047 | 0.182 | 0.21 | 0.024 | 0.12 | 0.097 | 0.062 | 0.014 | 0.101 |
| Income Tax Expense
| 12,110.2 | 6,848.5 | 7,256.3 | 20,097.7 | 9,135.2 | 7,268.5 | 8,182.7 | 7,596.5 | 7,443.7 | 5,965.9 | 3,634.5 | 827.1 | -888.1 | 2,251.2 | 1,913.6 | 213.6 | 536 | 43.6 | 273.7 | 130.3 | 457.1 |
| Net Income
| 31,729.7 | 19,275 | 26,481.5 | 53,348.4 | 28,451.4 | 23,647.3 | 24,231.7 | 23,016.6 | 19,820 | 15,757.7 | 11,728.5 | 2,938.6 | -1,235 | 5,634.5 | 5,634 | 1,002.6 | 2,384.8 | 2,009.6 | 697 | 32.5 | 1,086.8 |
| Net Income Ratio
| 0.109 | 0.078 | 0.113 | 0.217 | 0.125 | 0.123 | 0.15 | 0.157 | 0.145 | 0.131 | 0.146 | 0.051 | -0.027 | 0.129 | 0.158 | 0.033 | 0.098 | 0.095 | 0.044 | 0.002 | 0.072 |
| EPS
| 54.16 | 32.9 | 45.2 | 91.05 | 48.56 | 40.36 | 41.36 | 39.33 | 34.67 | 27.03 | 20.14 | 5.05 | -2.12 | 9.79 | 10.41 | 1.87 | 4.45 | 3.77 | 1.33 | 0.064 | 2.27 |
| EPS Diluted
| 54.16 | 32.9 | 45.2 | 91.05 | 48.56 | 40.36 | 41.36 | 39.33 | 34.66 | 27 | 20.11 | 5.05 | -2.12 | 8.81 | 8.91 | 1.55 | 3.53 | 3.03 | 1.25 | 0.064 | 2.26 |
| EBITDA
| 58,430 | 39,975.6 | 46,210 | 53,783.3 | 49,214.9 | 40,226 | 38,893.3 | 35,713.7 | 32,177.5 | 26,444.5 | 19,942.2 | 7,836 | 4,117.8 | 10,324.8 | 9,693.9 | 3,111.1 | 4,619 | 3,926.9 | 2,101.9 | 1,328.8 | 2,566.2 |
| EBITDA Ratio
| 0.201 | 0.162 | 0.198 | 0.219 | 0.216 | 0.209 | 0.24 | 0.244 | 0.236 | 0.22 | 0.248 | 0.136 | 0.09 | 0.236 | 0.271 | 0.101 | 0.19 | 0.185 | 0.132 | 0.101 | 0.171 |